Tardy mar­ket­ing ap­pli­ca­tion fil­ing, tri­al fail­ure trou­ble Su­per­nus in­vestors

Two key up­dates sur­faced in CNS-fo­cused Su­per­nus Phar­ma­ceu­ti­cals third-quar­ter re­sults on Tues­day.

The drug­mak­er has not yet filed a mar­ket­ing ap­pli­ca­tion for its AD­HD drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER